Quick Answer
Viking Therapeutics, Inc. reported Net Income Loss of -$359.64 million for the year ending 2025.
- Viking Therapeutics, Inc. showed a decrease of -227.1% in Net Income Loss from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$228.9 thousand | Q2 2014: -$22.78 million | Q3 2014: -$261.8 thousand | Q1 2015: -$5.71 million | Q2 2015: -$7.87 million | Q3 2015: -$4.74 million | Q1 2016: -$3.59 million | Q2 2016: -$3.69 million | Q3 2016: -$3.81 million | Q1 2017: -$5.22 million | Q2 2017: -$5.17 million | Q3 2017: -$6.10 million | Q1 2018: -$3.55 million | Q2 2018: -$6.67 million | Q3 2018: -$6.60 million | Q1 2019: -$4.92 million | Q2 2019: -$7.67 million | Q3 2019: -$5.73 million | Q1 2020: -$9.69 million | Q2 2020: -$9.57 million | Q3 2020: -$9.29 million | Q1 2021: -$14.01 million | Q2 2021: -$15.38 million | Q3 2021: -$13.24 million | Q1 2022: -$16.10 million | Q2 2022: -$17.43 million | Q3 2022: -$15.77 million | Q1 2023: -$19.53 million | Q2 2023: -$19.23 million | Q3 2023: -$22.53 million | Q1 2024: -$27.36 million | Q2 2024: -$22.25 million | Q3 2024: -$24.94 million | Q1 2025: -$45.63 million | Q2 2025: -$65.56 million | Q3 2025: -$90.79 million.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Net Income Loss has declined by 1,543.4%.
- Historical annual values: Fiscal year 2025: -$359.64 million | Fiscal year 2024: -$109.96 million | Fiscal year 2023: -$85.90 million | Fiscal year 2022: -$68.87 million | Fiscal year 2021: -$54.99 million | Fiscal year 2020: -$39.50 million | Fiscal year 2019: -$25.78 million | Fiscal year 2018: -$22.06 million | Fiscal year 2017: -$20.58 million | Fiscal year 2016: -$14.73 million | Fiscal year 2015: -$23.40 million | Fiscal year 2014: -$21.88 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: